Tramadol Use in Advanced Chronic Kidney Disease (eGFR < 30 mL/min/1.73 m²)

Guideline Recommendations

The Society for Perioperative Assessment and Quality Improvement (SPAQI) recommends against the use of tramadol in patients with renal insufficiency (eGFR < 30 mL/min/1.73 m²) and end‑stage renal disease because of the high risk of accumulation and toxicity. 1
When tramadol is deemed unavoidable in severe renal impairment, SPAQI advises using alternative opioids such as hydrocodone, oxycodone, or hydromorphone only with careful dose adjustment, or preferably selecting opioids without active metabolites (e.g., fentanyl, sufentanil, methadone). 1
SPAQI notes that methadone may be used but requires clinicians experienced with its pharmacokinetics due to the potential for drug accumulation. 1

Acetaminophen is the first‑line analgesic for patients with eGFR < 30 mL/min/1.73 m², with a recommended maximum dose of up to 3 g per day in chronic use, providing pain relief comparable to NSAIDs without nephrotoxicity or cardiovascular risk. 2
For severe pain requiring an opioid, fentanyl (transdermal or intravenous) is the safest option because it undergoes hepatic metabolism and does not produce active metabolites that accumulate in renal failure. 2
Buprenorphine (transdermal) is also considered safe; its metabolites are approximately 40 times less potent than the parent compound, minimizing the risk of renal accumulation. 2
Morphine and codeine should be avoided entirely in advanced CKD, as their glucuronide metabolites accumulate and can cause neurotoxicity and respiratory depression. 2

Tramadol combined with serotonergic agents (SSRIs, SNRIs, MAO inhibitors) markedly increases the risk of serotonin syndrome in patients with advanced CKD, who often take multiple medications. 1
CYP2D6 inhibitors (e.g., quinidine, fluoxetine, paroxetine) reduce conversion of tramadol to its active metabolite, potentially leading to inadequate analgesia. 1

Observe for signs of opioid toxicity such as excessive sedation, respiratory depression, or confusion. 1
Monitor for seizures, which are more likely with tramadol use in renal impairment. 1
Screen for serotonin syndrome symptoms (e.g., agitation, hyperreflexia, diaphoresis) when patients are on concurrent serotonergic drugs. 1

Do not employ standard tramadol dosing (50–100 mg every 4–6 h) in patients with eGFR < 30 mL/min/1.73 m², as this leads to drug accumulation and toxicity. 1
Do not assume tramadol is safer than other opioids in CKD; it still requires substantial dose reduction and carries unique risks (seizures, serotonin syndrome). 1
Do not co‑prescribe tramadol with NSAIDs in advanced CKD, because NSAIDs are contraindicated at eGFR < 30 mL/min/1.73 m². 2
Do not prescribe tramadol to patients already receiving maximal doses of SSRIs or SNRIs without evaluating the heightened risk of serotonin syndrome. 1